SCHEMBL2274895

SCHEMBL2274895

O=C(Nc1cc(-c2ccccc2)ccc1C(=O)O)c1cncc(-n2cccc2)c1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ACLY P53396 6/20 0.56
ALDH1A1 P00352 1/20 0.50
HDAC1 Q13547 5/20 0.48
DHODH Q02127 1/20 0.48
HDAC2 Q92769 4/20 0.47
HDAC3 O15379 2/20 0.47
SUCNR1 Q9BXA5 1/20 0.46
SERPINE1 P05121 3/20 0.45
KDM4D Q6B0I6 1/20 0.43
KDM4C Q9H3R0 1/20 0.43
MEN1 O00255 1/20 0.42
MAPT P10636 1/20 0.42
PKM P14618 1/20 0.42
GRIK1 P39086 1/20 0.42
KMT2A Q03164 1/20 0.42
TDP1 Q9NUW8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2268120 0.94 ACLY (0.48) ACLYALDH1A1HDAC1DHODHHDAC2
SCHEMBL2269570 0.91 ACLY (0.54) ACLYALDH1A1SUCNR1SERPINE1GRIK1
SCHEMBL2270475 0.87 HDAC1 (0.43) ACLYALDH1A1HDAC1HDAC2HDAC3
SCHEMBL12395652 0.86 ACLY (0.41) ACLYALDH1A1HDAC1DHODHHDAC2
SCHEMBL2269037 0.85 ACLY (0.59) ACLYHDAC1DHODHHDAC2HDAC3
SCHEMBL2272006 0.85 ACLY (0.62) ACLYHDAC1DHODHHDAC2HDAC3
SCHEMBL1315751 0.85 ACLY (0.64) ACLYALDH1A1HDAC1DHODHHDAC2
SCHEMBL12369599 0.84 HDAC2 (0.52) ACLYALDH1A1HDAC2SERPINE1MEN1
SCHEMBL2276851 0.84 CHRNB4 (0.45) ACLYALDH1A1HDAC1HDAC2SERPINE1
SCHEMBL2270812 0.84 ALDH1A1 (0.47) ALDH1A1SERPINE1KDM4DKDM4CMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 ACLY 653/4885ALDH1A1 645/4885HDAC1 71/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.